Q3 EPS Estimates for Pharming Group Reduced by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright lowered their Q3 2026 EPS estimates for shares of Pharming Group in a report issued on Thursday, July 30th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.20 for the quarter, down from their previous forecast of $0.30. The consensus estimate for Pharming Group’s current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Pharming Group’s FY2026 earnings at $0.40 EPS and FY2027 earnings at $0.50 EPS.

A number of other equities research analysts also recently commented on the company. Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Thursday. Canaccord Genuity Group increased their price target on shares of Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pharming Group has an average rating of “Hold” and a consensus target price of $38.67.

Pharming Group Trading Down 2.6%

Shares of PHAR opened at $9.82 on Monday. Pharming Group has a fifty-two week low of $9.62 and a fifty-two week high of $21.34. The company has a market capitalization of $695.06 million, a PE ratio of 81.83 and a beta of -0.01. The stock has a fifty day moving average of $12.97 and a two-hundred day moving average of $15.11. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.06 and a current ratio of 2.63.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The firm had revenue of $90.20 million for the quarter, compared to analyst estimates of $99.52 million. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHAR. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group in the 2nd quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new stake in Pharming Group in the fourth quarter valued at $224,000. Millennium Management LLC bought a new position in Pharming Group during the 4th quarter valued at $360,000. Finally, NewEdge Advisors LLC boosted its stake in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the last quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.